Filing Flows › Lexicon Pharmaceuticals (LXRX) › Q1 2025
Lexicon Pharmaceuticals (LXRX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
Lexicon Pharmaceuticals (LXRX) reported revenue of $1.3M for the first quarter 2025 (Q1 2025), +12% from a year earlier and -95% from the quarter before.
Lexicon Pharmaceuticals, Q1 2025: revenue $1.3M (+12% year over year), net loss $25.3M, operating cash flow −$43.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | -95% | +12% |
| Operating profit | −$25.7M | — | — |
| Net earnings | −$25.3M | — | — |
| Operating cash flow | −$43.8M | — | — |
What changed
Revenue was $1.3M in Q1 2025, up 12% year over year and down 95% from the previous quarter.
Operating costs exceeded revenue by $25.7M, an operating margin of -2034.8%. Total costs fell 42% while revenue rose 12%. The quarter ended with a net loss of $25.3M, narrower than the previous quarter's $33.8M loss.
Operating cash flow was −$43.8M. Non-cash charges added back $176K of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items used $21.7M.
Questions
What was Lexicon Pharmaceuticals' revenue in the first quarter 2025?
Lexicon Pharmaceuticals (LXRX) reported revenue of $1.3M for the first quarter 2025 (Q1 2025), +12% from a year earlier and -95% from the quarter before.